These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 29188576

  • 21. Cheminformatics in the Service of GPCR Drug Discovery.
    James T.
    Methods Mol Biol; 2018; 1705():395-411. PubMed ID: 29188575
    [Abstract] [Full Text] [Related]

  • 22. Structure versus function-The impact of computational methods on the discovery of specific GPCR-ligands.
    Bermudez M, Wolber G.
    Bioorg Med Chem; 2015 Jul 15; 23(14):3907-12. PubMed ID: 25828056
    [Abstract] [Full Text] [Related]

  • 23. Virtual Screening of Human Class-A GPCRs Using Ligand Profiles Built on Multiple Ligand-Receptor Interactions.
    Chan WKB, Zhang Y.
    J Mol Biol; 2020 Aug 07; 432(17):4872-4890. PubMed ID: 32652079
    [Abstract] [Full Text] [Related]

  • 24. Characterizing common substructures of ligands for GPCR protein subfamilies.
    Erguner B, Hattori M, Goto S, Kanehisa M.
    Genome Inform; 2010 Aug 07; 24():31-41. PubMed ID: 22081587
    [Abstract] [Full Text] [Related]

  • 25. Extended template-based modeling and evaluation method using consensus of binding mode of GPCRs for virtual screening.
    Sato M, Hirokawa T.
    J Chem Inf Model; 2014 Nov 24; 54(11):3153-61. PubMed ID: 25350693
    [Abstract] [Full Text] [Related]

  • 26. Computational approaches for ligand discovery and design in class-A G protein- coupled receptors.
    Rodríguez D, Gutiérrez-de-Terán H.
    Curr Pharm Des; 2013 Nov 24; 19(12):2216-36. PubMed ID: 23016842
    [Abstract] [Full Text] [Related]

  • 27. Identifying ligands at orphan GPCRs: current status using structure-based approaches.
    Ngo T, Kufareva I, Coleman JLj, Graham RM, Abagyan R, Smith NJ.
    Br J Pharmacol; 2016 Oct 24; 173(20):2934-51. PubMed ID: 26837045
    [Abstract] [Full Text] [Related]

  • 28. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols.
    Evers A, Hessler G, Matter H, Klabunde T.
    J Med Chem; 2005 Aug 25; 48(17):5448-65. PubMed ID: 16107144
    [Abstract] [Full Text] [Related]

  • 29. Assessing GPCR homology models constructed from templates of various transmembrane sequence identities: Binding mode prediction and docking enrichment.
    Loo JSE, Emtage AL, Ng KW, Yong ASJ, Doughty SW.
    J Mol Graph Model; 2018 Mar 25; 80():38-47. PubMed ID: 29306746
    [Abstract] [Full Text] [Related]

  • 30. A Pharmacochaperone-Based High-Throughput Screening Assay for the Discovery of Chemical Probes of Orphan Receptors.
    Morfa CJ, Bassoni D, Szabo A, McAnally D, Sharir H, Hood BL, Vasile S, Wehrman T, Lamerdin J, Smith LH.
    Assay Drug Dev Technol; 2018 Oct 25; 16(7):384-396. PubMed ID: 30251873
    [Abstract] [Full Text] [Related]

  • 31. QSAR modeling of GPCR ligands: methodologies and examples of applications.
    Tropsha A, Wang SX.
    Ernst Schering Found Symp Proc; 2006 Oct 25; (2):49-73. PubMed ID: 17703577
    [Abstract] [Full Text] [Related]

  • 32. Modeling G protein-coupled receptors for structure-based drug discovery using low-frequency normal modes for refinement of homology models: application to H3 antagonists.
    Rai BK, Tawa GJ, Katz AH, Humblet C.
    Proteins; 2010 Feb 01; 78(2):457-73. PubMed ID: 19787776
    [Abstract] [Full Text] [Related]

  • 33. Structure-Based Virtual Screening for Ligands of G Protein-Coupled Receptors: What Can Molecular Docking Do for You?
    Ballante F, Kooistra AJ, Kampen S, de Graaf C, Carlsson J.
    Pharmacol Rev; 2021 Oct 01; 73(4):527-565. PubMed ID: 34907092
    [Abstract] [Full Text] [Related]

  • 34. A benchmarking study on virtual ligand screening against homology models of human GPCRs.
    Lim VJY, Du W, Chen YZ, Fan H.
    Proteins; 2018 Sep 01; 86(9):978-989. PubMed ID: 30051928
    [Abstract] [Full Text] [Related]

  • 35. Homology modeling of G-protein-coupled receptors with X-ray structures on the rise.
    Yarnitzky T, Levit A, Niv MY.
    Curr Opin Drug Discov Devel; 2010 May 01; 13(3):317-25. PubMed ID: 20443165
    [Abstract] [Full Text] [Related]

  • 36. Discovery of GPCR Ligands by Molecular Docking Screening: Novel Opportunities Provided by Crystal Structures.
    Rodríguez D, Ranganathan A, Carlsson J.
    Curr Top Med Chem; 2015 May 01; 15(24):2484-503. PubMed ID: 26126906
    [Abstract] [Full Text] [Related]

  • 37. Challenges and Opportunities in Drug Discovery of Biased Ligands.
    Rodríguez-Espigares I, Kaczor AA, Stepniewski TM, Selent J.
    Methods Mol Biol; 2018 May 01; 1705():321-334. PubMed ID: 29188569
    [Abstract] [Full Text] [Related]

  • 38. New Trends in Inspecting GPCR-ligand Recognition Process: the Contribution of the Molecular Modeling Section (MMS) at the University of Padova.
    Ciancetta A, Cuzzolin A, Deganutti G, Sturlese M, Salmaso V, Cristiani A, Sabbadin D, Moro S.
    Mol Inform; 2016 Sep 01; 35(8-9):440-8. PubMed ID: 27546048
    [Abstract] [Full Text] [Related]

  • 39. Automated Inference of Chemical Discriminants of Biological Activity.
    Raschka S, Scott AM, Huertas M, Li W, Kuhn LA.
    Methods Mol Biol; 2018 Sep 01; 1762():307-338. PubMed ID: 29594779
    [Abstract] [Full Text] [Related]

  • 40. Investigating Small-Molecule Ligand Binding to G Protein-Coupled Receptors with Biased or Unbiased Molecular Dynamics Simulations.
    Marino KA, Filizola M.
    Methods Mol Biol; 2018 Sep 01; 1705():351-364. PubMed ID: 29188572
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.